Ligand Pharmaceuticals (LGND) Receivables - Other (2017 - 2018)
Ligand Pharmaceuticals' (LGND) quarterly Receivables - Other came in at $8.0 million in Q4 2018, up 60.0% quarter-over-quarter from $5.0 million in Q3 2017.
Ligand Pharmaceuticals (LGND) Receivables - Other (2017 - 2018) Analysis & Trends
Ligand Pharmaceuticals has disclosed Receivables - Other across 2 years of filings, most recently posting $8.0 million for Q4 2018.
- Receivables - Other for Q4 2018 came in at $8.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $8.0 million (changed N/A YoY), and the FY2018 annual result was $8.0 million, changed N/A from the prior year.
- Receivables - Other came in at $8.0 million for Q4 2018 at Ligand Pharmaceuticals, up from $5.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $8.0 million in Q4 2018 to a low of $5.0 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.47 Bn | 4.69 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 8.00 Mn |
| Dec 31, 2018 | 8.00 Mn |
| Sep 30, 2017 | 5.00 Mn |
| Sep 30, 2017 | 5.00 Mn |
| Jun 30, 2017 | 5.00 Mn |
| Jun 30, 2017 | 5.00 Mn |